Skip to main content
Journal cover image

Comparison of outcomes for African Americans, Hispanics, and Non-Hispanic Whites in the CATIE study.

Publication ,  Journal Article
Arnold, JG; Miller, AL; Cañive, JM; Rosenheck, RA; Swartz, MS; Mintz, J
Published in: Psychiatr Serv
June 2013

OBJECTIVE: Medication outcome literature in schizophrenia across racial-ethnic groups is sparse, with inconsistent findings. The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study provided an opportunity for exploratory analyses of racial-ethnic outcomes. The study objective was to examine race-ethnicity outcomes for CATIE's main outcome (study discontinuation) and secondary outcomes. METHODS: CATIE participants included whites (non-Hispanic) (N=722), African Americans (N=506), and Hispanics (N=170). Survival analyses and mixed-effects regression modeling were conducted, with adjustment for baseline sociodemographic differences and baseline scores of the secondary outcomes. RESULTS: Racial-ethnic groups had unique patterns of outcomes. Hispanics were much more likely to discontinue for lack of efficacy from perphenazine (64% versus 42% non-Hispanic whites and 24% African Americans) and ziprasidone (71% versus 40% non-Hispanic whites and 24% African Americans); Hispanics' quality of life also declined on these medications. Non-Hispanic whites were more likely to discontinue for lack of efficacy in general (averaging olanzapine, quetiapine, and risperidone discontinuation rates). African Americans were less likely to continue after the first phase (32% continuing versus 40% for non-Hispanic whites and 41% Hispanics). Discontinuations were driven by research burden, personal issues, and unspecified loss to follow-up. Non-Hispanic whites had higher depression scores during the follow-up period. African Americans had fewer side effects. CONCLUSIONS: CATIE results did not show disparities favoring non-Hispanic whites. CATIE may have provided state-of-the-art treatment and thus reduced disparate treatments observed in community clinics. African Americans discontinued even after consideration of socioeconomic differences. Why perphenazine and ziprasidone may be less effective with Hispanics should be explored.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Psychiatr Serv

DOI

EISSN

1557-9700

Publication Date

June 2013

Volume

64

Issue

6

Start / End Page

570 / 578

Location

United States

Related Subject Headings

  • Young Adult
  • White People
  • United States
  • Thiazoles
  • Schizophrenia
  • Psychiatry
  • Piperazines
  • Perphenazine
  • Patient Dropouts
  • Outcome Assessment, Health Care
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Arnold, J. G., Miller, A. L., Cañive, J. M., Rosenheck, R. A., Swartz, M. S., & Mintz, J. (2013). Comparison of outcomes for African Americans, Hispanics, and Non-Hispanic Whites in the CATIE study. Psychiatr Serv, 64(6), 570–578. https://doi.org/10.1176/appi.ps.002412012
Arnold, Jodi Gonzalez, Alexander L. Miller, José M. Cañive, Robert A. Rosenheck, Marvin S. Swartz, and Jim Mintz. “Comparison of outcomes for African Americans, Hispanics, and Non-Hispanic Whites in the CATIE study.Psychiatr Serv 64, no. 6 (June 2013): 570–78. https://doi.org/10.1176/appi.ps.002412012.
Arnold JG, Miller AL, Cañive JM, Rosenheck RA, Swartz MS, Mintz J. Comparison of outcomes for African Americans, Hispanics, and Non-Hispanic Whites in the CATIE study. Psychiatr Serv. 2013 Jun;64(6):570–8.
Arnold, Jodi Gonzalez, et al. “Comparison of outcomes for African Americans, Hispanics, and Non-Hispanic Whites in the CATIE study.Psychiatr Serv, vol. 64, no. 6, June 2013, pp. 570–78. Pubmed, doi:10.1176/appi.ps.002412012.
Arnold JG, Miller AL, Cañive JM, Rosenheck RA, Swartz MS, Mintz J. Comparison of outcomes for African Americans, Hispanics, and Non-Hispanic Whites in the CATIE study. Psychiatr Serv. 2013 Jun;64(6):570–578.
Journal cover image

Published In

Psychiatr Serv

DOI

EISSN

1557-9700

Publication Date

June 2013

Volume

64

Issue

6

Start / End Page

570 / 578

Location

United States

Related Subject Headings

  • Young Adult
  • White People
  • United States
  • Thiazoles
  • Schizophrenia
  • Psychiatry
  • Piperazines
  • Perphenazine
  • Patient Dropouts
  • Outcome Assessment, Health Care